Abstracts tagged "medical necessity and biologic drugs"

Abstract Number: 1813 • 2019 ACR/ARP Annual Meeting
New Medications Are Needed for Children with Juvenile Idiopathic Arthritis
Hermine Brunner¹, Laura Schanberg ², Yukiko Kimura ³, Anne Dennos ⁴, Guy Eakin ⁵, Dominic Co ⁶, Robert Colbert ⁷, Robert Fuhlbrigge ⁸, Ellen Goldmuntz ⁹, Daniel Kingsbury ¹⁰, Sandra Mintz ¹¹, Karen Onel ¹², Cathy Patty-Resk ¹³, Lisa G. Rider ¹⁴, Rayfel Schneider ¹⁵, Allen Watts ¹⁶, Emily von-Scheven ¹⁷, Daniel J. Lovell ¹⁸, Timothy Beukelman ¹⁹ and for PRCSG Advisory Council and CARRA Registry Investigators ²⁰, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Duke University Medical Center, Durham, NC, ³Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Cincinnati, OH, ⁴Duke Clinical Research Institute, Durham, NC, ⁵Arthritis Foundation, Atlanta, ⁶of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD, ⁸Department of Rheumatology, Children’s Hospital Colorado, Denver, CO, ⁹NIAID, Washingto, DC, ¹⁰LHS Pediatrics, Prtland, OR, ¹¹Children's Hospital of Los Angeles, Los Angeles, CA, ¹²Hospital for Special Surgery, Division of Pediatric Rheumatology, New York, NY, ¹³Children's Hospital of Michigan, Detroit, MI, ¹⁴Environmental Autoimmunity Group, Clinical Research Branch, NIEHS, NIH, Bethesda, MD, ¹⁵Hospital for Sick Children, Toronto, ON, Canada, ¹⁶Cincinnati Children's Hospital MEdical Center, Cincinnati, OH, ¹⁷University of California San Francisco, San Francisco, ¹⁸Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, ¹⁹University of Alabama Birmingham, Birmingham, AL, ²⁰Pediatric Rheumatology Collaborative Study Group, Cincinnati, OH
Background/Purpose: Existing legislation in the United States (US) promotes the study of new medications in children. Biologic disease-modifying-drugs (bDMARDs) and small molecules proven effective and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].